Terms: = Pancreatic cancer AND TRD
4 results:
1. pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior.
Sahin IH; Elias H; Chou JF; Capanu M; O'Reilly EM
BMC Cancer; 2018 Jul; 18(1):769. PubMed ID: 30055578
[TBL] [Abstract] [Full Text] [Related]
2. Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma - in vitro and in vivo.
Buchholz M; Majchrzak-Stiller B; Hahn S; Vangala D; Pfirrmann RW; Uhl W; Braumann C; Chromik AM
BMC Cancer; 2017 Mar; 17(1):216. PubMed ID: 28340556
[TBL] [Abstract] [Full Text] [Related]
3. Taurolidine induces epithelial-mesenchymal transition via up-regulation of the transcription factor Snail in human pancreatic cancer cell lines.
Hotz B; Erben U; Arndt M; Buhr HJ; Hotz HG
Int J Colorectal Dis; 2014 Nov; 29(11):1339-48. PubMed ID: 25179425
[TBL] [Abstract] [Full Text] [Related]
4. Taurolidine reduces the tumor stimulating cytokine interleukin-1beta in patients with resectable gastrointestinal cancer: a multicentre prospective randomized trial.
Braumann C; Gutt CN; Scheele J; Menenakos C; Willems W; Mueller JM; Jacobi CA
World J Surg Oncol; 2009 Mar; 7():32. PubMed ID: 19309495
[TBL] [Abstract] [Full Text] [Related]
